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In this study the mechanism of nuclear importation of the splicing factor PRPF31 is examined and the impact of two disease-linked mutations,
A194E and A216P, assessed. Using pull-down assays with GST-tagged importin proteins, we demonstrate that His-tagged PRPF31 interacts with
importin β1 for translocation to the nucleus, with no requirement for importin α1. The A194E and A216P mutations have no affect on this
interaction. Fluorescence recovery after photobleaching (FRAP) was used to estimate the rate of movement of EGFP-tagged PRPF31 into the
nuclei of live cells. The kinetics indicated a two-component recovery process; a fast component with τ ∼ 6 s and a slow component with τ ∼ 80 s.
The mutations affected neither component. We conclude that the two mutations have no negative effect on interaction with the nuclear importation
machinery. Reduced mutant protein solubility resulting in an insufficiency of splicing activity in cells with a very high metabolic demand remains
the most likely explanation for the disease pathology in ADRP patients.
© 2005 Elsevier B.V. All rights reserved.Keywords: PRPF31; Retinitis pigmentosa; Nuclear transport; FRAP1. Introduction
Retinitis pigmentosa (RP) is a clinically and genetically
heterogeneous group of generally progressive diseases of the
retina. Initially, only the rod cells of the scotopic system are
affected but subsequently both peripheral and central cones
used in bright light vision may be affected, often leading to
complete blindness. Clinical manifestations include pigment
deposition in the retina and attenuation of retinal blood vessels,
with later depigmentation or atrophy of the RPE. With an
incidence of 1 in 3500 of the population, inheritance may be X-
linked, autosomal dominant or autosomal recessive. Mutations
within six genes (RHO, peripherin/RDS, RP1, NRL, CRX and
FSCN2) encoding proteins uniquely expressed in photoreceptorAbbreviations: PRPF31, pre-RNA splicing protein factor 31; ADRP,
autosomal dominant retinitis pigmentosa; EGFP, enhanced green fluorescent
protein; GST, glutathione sulphotransferase
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forms of the disease. However, not all ADRP genes show a
restricted pattern of expression and a number of ubiquitously
expressed genes have been linked to the disease, including the
mRNA splicing factor genes PRPF31 [1], PRPC8 [2] and
HPRP3 [3]. An intriguing aspect to the association of these
latter genes with retinal disease is the fact that splicing occurs in
every cell of the body and the genes thus have a general
housekeeping function, yet the disease pathology is restricted to
the rod photoreceptors of the retina.
The splicing of pre-mRNA in the nucleus is catalysed by a
large ribonucleoprotein complex, the spliceosome, consisting
of the pre-mRNA substrate and several small nuclear
ribonucleoproteins (snRNPs) together with splicing factors
not integrated into snRNPs. Splicing of the vast majority of
introns involves five snRNPs, U1, U2, U4, U5 and U6.
Spliceosome assembly involves firstly the binding of U1 and
U2 to the pre-mRNA substrate with the formation of a pre-
splicing complex (complex A), followed by binding of a trimer
of U4/U5+U6 to form the spliceosome proper (complex B).
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61-kDa protein (PRPF31, also known as splicing factor 61K
[4]), which is an integral component of the U4/U6+U5 tri-
snRNP. Interestingly the other two splicing factor proteins
linked to ADRP (HPRP3 and PRPC8) are also components of
the same tri-snRNP [5–7].
Our previous work has focused on the functional
consequences of the two missense disease-causing mutations
in PRPF31, A194E and A216P, originally reported by
Vithana et al. [8]. Using a yeast complementation assay, we
showed that the introduction of the human A216P mutation
into the yeast orthologue PRP31p effects only a partial
rescue, although the mutant protein appears to be non-toxic
in yeast even when highly expressed. We also found no
evidence for any dominant negative effect in terms of
splicing efficiency or accuracy attributable to either
mutation, although a recent study using rod opsin mini-
genes [9] indicates that there may be a direct effect of
mutant splicing factor on the efficiency of splicing for some
introns but not for others. Nevertheless, protein localisation
studies in mammalian cells transfected with His-tagged
PRPF31 constructs show mislocation of the mutant proteins,
with a substantial proportion in the cytoplasm rather than
the nucleus [8]. Western analysis also demonstrated that less
soluble PRPF31 protein was present in the nucleus. We
therefore postulated that this could be due to a defect in the
trafficking of the mutant proteins to the nucleus. Further-
more, we suggested that insufficiency of splicing function
may be the origin of the pathology. To explain the limitation
of pathology to the retina, we proposed that the functional
insufficiency arising from mutations in PRPF31 is only
revealed under conditions of elevated splicing demand. With
the need to replenish disc proteins on a daily basis, such
conditions will exist in rod photoreceptors and this may
underlie the pathology.
In this study, we have examined the process whereby
PRPF31 is trafficked within the cell and the effects of
the two disease causing mutations A194E and A216P on
this process. PRPF31 contains a classical nuclear localisa-
tion sequence (NLS) between residues 351 and 364
(351RKKRGGRRYRKMKE364), as first identified from
computer prediction software [1] and subsequently con-
firmed by generation of a deletion mutant (ΔNLS) in
which this 14-residue sequence was deleted [8]. Targeting
to the nucleus involves interaction of this NLS with one of
a family of importin proteins, which carries the protein to
the nuclear envelope where interaction with Ran.GTP
mediates transport through the pore into the nucleus
(reviewed in [10]). Here, we show that purified PRPF31
interacts with importin β1, but that this interaction does not
appear to be affected by the two mutations A194E or
A216P. Moreover, the mutations do not appear to affect the
rate of nuclear importation of PRPF31 in live cells. Thus,
the protein mislocation reported earlier [8] is not due to a
failure of the mutant proteins to interact with the nuclear
importation machinery, but instead arises from reduced
protein solubility.2. Materials and methods
2.1. Reagents
Oligonucleotides used as PCR primers were purchased from Sigma-
Genosys, Cambridge, UK. The nucleotide sequences of all primers used in
this study may be obtained by application to the authors. Restriction enzymes
were supplied by Promega, Southampton, UK. Except where otherwise
stated, all other chemicals and reagents were purchased from Sigma-Aldrich,
Poole, UK.
2.2. Plasmid construction
Full-length importin α cDNA was amplified from pRSET-hSRP1α [11]
using primer pair 5′Impα/3′Impα, inserted into the TA cloning vector
pGEM.Teasy (Promega, Southampton, UK) and then transferred as a
BamHI–EcoRI digest fragment into the expression vector pGEX6P-1
(Amersham Biosciences, Little Chalfont, UK) to generate the construct
pGEX-Impα. Full-length importin β cDNA was amplified similarly from the
plasmid pET30.Impβ [12] using primers 5′Impβ/3′Impβ and then inserted
as a BamHI–XhoI digest fragment into pGEX6P-1 to yield the construct
pGEX-Impβ.
The full-length wild type PRPF31 coding sequence was amplified from
pTriEx.PRPF31.His using primers EGFPN1F (BglII-tagged) and EGFPN1R
(XhoI/EcoRI-tagged) and inserted into pEGFP-N1 (Clontech, Basingstoke,
UK) via the BglII and EcoRI sites to yield the construct pPRPF31-EGFP.
Mutant versions of this construct containing the substitutions A194E and
A216P were generated by removing the HindIII–XhoI digest fragment from
pPRPF31-EGFP and replacing it with corresponding fragments from mutant
versions of pTriEx.PRPF31.His.
2.3. Purification of wild type His-tagged PRPF31 expressed in HEK
293T cells
HEK 293T cells (ECACC) were transiently transfected with pTriEx.
PRPF31.His in 135 mm diameter tissue culture dishes using the GeneJuice
transfection reagent (Merck Biosciences Ltd., Nottingham, UK). Cells were
harvested 48 h later, washed 3× with phosphate buffered saline (PBS) and
stored as a cell pellet at −20 °C. The cell pellet from 8 dishes of cells was
resuspended in 4 ml 1× Bind buffer (1 M NaCl, 20 mM Tris–HCl, 5 mM
imidazole, pH 7.9), the cells lysed by sonication and the soluble protein
extract collected by centrifugation at 18,500×g for 30 min at 4 °C. This
extract was filtered and then applied to a 2.5 ml (bed volume) His.Bind
column (Merck Biosciences Ltd., Nottingham, UK) charged with NiSO4.
The purification was performed according to the manufacturer's instructions,
washing the column with 100 mM imidazole buffer prior to eluting the
purified His-tagged PRPF31 off the column with 1× Elute buffer (1 M
imidazole, 500 mM NaCl, 20 mM Tris–HCl, pH 7.9). A PD10 column
(Amersham-Biosciences, Little Chalfont, UK) was then used to remove
imidazole and effect buffer exchange to HEPES buffer (10 mM HEPES, 3.4
mM EDTA, 150 mM NaCl, 0.005% Tween, pH 7.4). Throughout the
elution and buffer exchange steps, care was taken to minimise dilution of
the protein, since downstream protein concentration using commercial
microconcentrators always led to loss of product. Protein concentrations of
all extracts were determined using a BioRad protein assay kit (BioRad
Laboratories Ltd., Hemel Hempstead, UK) with γ-immunoglobulin as
standard.
2.4. Purification of wild type and mutant His-tagged PRPF31
expressed in E. coli
E. coli strain Tuner (DE3) pLacI cells (Merck Biosciences Ltd., Nottingham,
UK) were transformed with wild type or mutant pTriEx.PRPF31.His and grown
in LB supplemented with chloramphenicol, ampicillin and 1% glucose to OD600
of 0.6–0.8. After induction with 0.1 mM IPTG, the cells were grown for a
further 3 h at 37 °C before harvest. Inclusion bodies (containing insoluble His-
tagged PRPF31) were isolated from a 200 ml aliquot of culture as described in
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in 5 ml 1× Bind buffer containing 6 M urea for 1 h at 4 °C and centrifuged at
16,000×g for 30 min to remove insoluble material. The soluble extract was
then filtered and applied to a 2.5 ml (bed volume) His.Bind column pre-
charged with NiSO4 and equilibrated with 1× Bind buffer containing 6 M urea.
After washing with 1× Bind buffer (+6 M urea) and with 200 mM imidazole
buffer (+6 M urea), the denatured, His-tagged PRPF31 was eluted off the
column with 1× Elute buffer (+6 M urea). The protein concentration of the
denatured protein extract was then reduced to 0.2 mg/ml with 1× Bind buffer
(+6 M urea) and the extract dialysed in a Pierce Slide-A-Lyser cassette (PerBio
Science UK Ltd., Cramlington, UK) against HEPES buffer containing reducing
concentrations of urea. The protein concentration of the dialysed extract was
around 0.1 mg/ml.
2.5. Purification of GST-tagged importin proteins
GST and GST-tagged Impα and Impβ were expressed from the above
pGEX constructs in E. coli strain BL21 (DE3) cells. Liquid cultures were
grown to log phase, induced with 0.1 mM IPTG and then grown overnight at
25 °C. In each case, the proteins were purified from a 20-ml aliquot of culture
using a GST purification module (Amersham Biosciences, Little Chalfont,
UK) and a batch procedure described in the manufacturer's instructions. 200
μl 50% glutathione sepharose slurry was used per purification and the GST-
tagged protein was eluted off the resin using 2×250 μl reduced glutathione
buffer. Glutathione was removed from the protein by passage through a PD10
column (Amersham Biosciences, Little Chalfont, UK), eluting with PBS. The
purified protein was concentrated to at least 0.5 mg/ml using a YM10
Centricon column (Millipore (UK) Ltd. Watford, UK) passivated with 5%
polyethylene glycol.
2.6. Pull-down assays
0.1 nmol of purified His-tagged PRPF31 or 10 units of human recombinant
NF-κβ protein (Sigma-Aldrich, Poole, UK) were mixed with 0.1 nmol of
purified GST-tagged importin protein or purified GST (negative control) in a
total volume of 100 μl PBS. The mixture was rotated for 1 h at 4 °C. 20 μl of
50% glutathione sepharose beads were then added and rotation was continued
for a further 30 min. The beads were centrifuged and washed 3 times with pre-
chilled PBS. Bound proteins were eluted with 2×10 μl aliquots of reduced
glutathione buffer. The combined fractions were mixed with SDS sample buffer
and analysed by SDS-PAGE. Bound proteins were either stained with
Coomassie or subjected to Western analysis as follows. Aliquots were separated
in 12% SDS-PAGE gels and were then blotted on to Hybond ECL membrane
(Amersham Biosciences, Little Chalfont, UK) using transfer buffer [50 mM Tris
pH 9.1, 390 mM glycine, 0.04% SDS, 20% methanol]. Blots were blocked with
5% (w/v) dried milk proteins in PBS/0.1% Tween. For detection of His-tagged
PRPF31 proteins, blots were probed with Penta.His antibody (Qiagen Ltd.,
Crawley, UK) at a dilution of 1:2000 followed, after washing, by an HRP-
conjugated anti-mouse secondary antibody (Pierce Biochemicals Inc., Rochford,
USA) at a dilution of 1:5000. For detection of NF-κβ, blots were probed with
anti-NF-κB antibody (Merck Biosciences, Nottingham, UK) at a dilution of
1:500, followed after washing with an anti-rabbit HRP secondary antibody
(Pierce Biochemicals Inc., Rochford, USA) at dilution of 1:15,000. Blots were
developed with ECL-Plus HRP detection system (Amersham Biosciences, Little
Chalfont, UK).
2.7. Western blot analyses of soluble cell lysates
Transfected HEK 293 T cells were harvested and sonicated in lysis buffer
(20 mM HEPES pH 7.4, 0.4 mM EDTA, 450 mM NaCl, 0.5 mM DTT, 0.5 mM
PMSF) to produce whole cell lysates. They were then spun at 13 K rpm in a
chilled microfuge for 10 min and the soluble fractions removed to clean tubes.
The protein contents of these soluble lysates were measured using a Biorad
protein assay kit and were equalised by addition of further lysis buffer. Aliquots
containing 10 μg protein were separated by SDS-PAGE electrophoresis, blotted
and blocked as described above. Detection of His-tagged PRPF31 proteins was
also as described above. For detection of EGFP-tagged PRPF31 proteins, blots
were probed with an anti-EGFP monoclonal antibody (Abcam Ltd., Cambridge,UK) at a dilution of 1:5,000,000 followed by the same HRP-conjugated anti-
mouse secondary antibody as used for the Penta.His antibody.
2.8. Fluorescence recovery after photobleaching (FRAP) analysis
COS7 cells were transfected with pPRPF31-EGFP constructs using
GeneJuice in 3.5 cm glass bottom Microwell dishes (MatTek Corporation,
Ashland, MA, USA) and grown for 24 h at 37 °C. 30 min prior to FRAP analysis
the medium was changed to DMEM (without methyl red) supplemented with 50
μg/ml cyclohexiimide. Confocal imaging of EGFP-tagged proteins in the live
cells was performed using a BioRad Radiance 2000 laser scanning microscope
operated via Lasersharp v5.1 confocal imaging software and the Time-Course
and Patterned Illumination option. The cells were visualised by a Zeiss Axiovert
microscope using a Zeiss 63× Plan Apochromat oil immersion objective, a 488
nm laser-line excitation, and a narrow band 515–545 nm emission filter placed
in front of the detector PMT. Image magnification could be further increased
using the Bio-Rad optical zoom function (1 to 10×). All live-cell confocal
imaging experiments were conducted at 37 °C in a thermostatically controlled
incubator chamber, which was purged with 5% CO2 in air and set up on the
microscope XY stage. For FRAP analysis a region of interest (ROI) consisting
of the area occupied by the nucleus at its widest point was selected. After a
single pre-bleach imaging scan of the entire cell, the ROI was photobleached
using 3 cycles of maximum laser power (50 mW) with t=0 s between cycles.
The microscope was then immediately switched to imaging mode and time lapse
sequences were recorded every 1 s for 10 cycles and then every 10 s for 20
cycles. Laser power used for imaging was b5% of maximum. Data acquisition
was at 750 lines per second (lps) and each image was recorded twice and
optimised using Kalman filtering (an averaging of sequential images to reduce
noise). Control experiments in which an unbleached ROI was subjected to time
lapse imaging under similar conditions indicated that photobleaching during
normal data acquisition was not significant during the time course of the
experiment. The kinetics of fluorescence recovery after nuclear photobleaching
was determined from the variation in average fluorescence intensity in the ROI
over time after photobleaching. Fluorescence intensities were normalised to the
pre-bleach values, which were arbitrarily set to 1.3. Results
3.1. Purification of wild type and mutant PRPF31.His proteins
Wild type and mutant PRPF31.His proteins were expressed
as recombinant proteins in HEK 293 T cells. The wild type
protein was purified to homogeneity (∼95% purity) in a single
step from a crude extract of soluble proteins from the cells using
Ni2+ affinity chromatography (see Fig. 1a, lane 1). After
desalting and buffer exchange, the maximum protein concen-
tration achieved, however, was only around 0.1 mg/ml, and the
purification of mutant protein A216P and A194E under the
same conditions yielded very little protein (see Fig. 1a, lane 2).
Attempts to increase protein yield using commercial protein
concentrators were unsuccessful due to protein precipitation or
adherence of protein to the membrane. We were, however, able
to purify both wild type and mutant proteins under denaturing
conditions from inclusion bodies to yield soluble denatured
protein in good yield (Fig. 1a, lanes 3 and 4). When the
denaturant was removed by dialysis, soluble renatured protein
was obtained for both wild type and mutant in similar yield (Fig.
1a, lanes 5 and 6). Note, however, that it was necessary to
reduce the protein concentration to less than 0.2 mg/ml during
dialysis to minimise protein loss due to precipitation, and for the
same reason, subsequent concentration of the renatured protein
above ∼0.1 mg/ml was not possible.
Fig. 1. Purification of PRPF31.His proteins and pull down assays with importin proteins. (a) Wild type (lane 1) and A216P mutant (lane 2) PRPF31 proteins expressed
in HEK 293T cells and purified using His.bind columns under non-denaturing conditions, and wild type (lanes 3 and 5) and A216P mutant (lanes 4 and 6) proteins
expressed in E. coli and purified from inclusion bodies by elution from His.bind columns (denatured—lanes 3 and 4) or after removal of denaturant by dialysis (soluble
renatured proteins—lanes 5 and 6). (b) Coomassie blue stained SDS-PAGE gel showing binding of wild type PRPF31.His to GST-tagged importin β1 (lane 2), to an
importin α1/importin β1 mixture (lane 3), but not to importin α1 alone (lane 1). (c) Western analysis of human recombinant NF-Kβ protein showing binding to an
importin α1/importin β1 mixture (lane 1) but not to importin β1 alone (lane 2). Upper panel was probed with an NF-Kβ antibody and lower panel with α-GST
antibody. (d) Western analysis of mutant PRPF31.His proteins after elution from immobilised GST-importin β1. Upper panel was probed with α-His.tag antibody and
lower panel with α-GST antibody. M denotes marker lanes with purified proteins.
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PRPF31 contains a classical NLS but it is unknown which of
the family of importin proteins is used to facilitate importation
into the nucleus. Most proteins with classical NLSs interact with
a heterodimer of importin α and importin β (reviewed in
[10]). The NLS-binding site is on the α sub-unit, but binding is
inhibited by an N-terminal sub-unit comprising the first 49
residues, which binds the β sub-unit. Binding of importin β
relieves the inhibition and allows binding of the cargo protein
via its NLS. Importin β is also responsible for translocation of
the importin–cargo complex through the nuclear pore and, once
inside the nucleus, importin β interacts with Ran-GTP to effect
dissociation of the cargo protein into the nucleoplasm.
To examine the nuclear importation mechanism used for
PRPF31, full-length human importin α1 and importin β1 were
expressed with N-terminal GST tags in bacterial cells. The GST-
tags were used to purify the proteins using glutathione-
sepharose affinity chromatography. The importin proteins
bound to glutathione-sepharose were then used to precipitate
purified wild type PRPF31.His obtained from inclusion bodies
and the precipitates were analysed by SDS PAGE with
Coomassie blue staining (Fig. 1b). A band corresponding toPRPF31.His was seen using importin β1, both on its own (lane
2) and in combination with importin α1 (lane 3). As expected,
importin α1 alone did not precipitate the PRPF31.His (lane 1).
No detectable precipitation occurred in a control reaction
without importin (lane 4), indicating that non-specific binding
of the PRPF31.His to the glutathione-sepharose was minimal.
These results indicate therefore that importation of PRPF31 into
the nucleus involves binding to importin β1 alone with no
absolute requirement for importin α1.
In order to confirm that recombinant importin α1 was active
in binding target proteins, the experiments were repeated with
human recombinant NF-κβ, a transcription factor that is a
known target for importin α [13]. As shown in Fig. 1c, NF-κβ
was recovered in pull-down assays with an importin α1/
importin β1 mixture (lane 1), but not with importin β1 alone
(lane 2), demonstrating therefore the functionality of importin
α1 and that importin β1 does not bind non-specifically.
Binding of wild type and mutant PRPF31.His to GST-
importin β1 was compared using similar pull-down assays, but
in this case gels were blotted and probed with anti-His.tag and
anti-GST.tag antibodies for the detection step (Fig. 1d). The
A194E and A216P mutations did not appear to affect binding to
GST-importin β1. Control reactions with GST protein alone
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type and mutant PRPF31.His to the GST tag was negligible.
3.3. Effect of purification tags on expression and solubility of
PRPF31
Our previous studies have indicated that, when expressed
with a His-tag, the A194E and A216P mutations resulted in
protein insolubility compared to wild type [8]. In contrast, the
following experiment shows that, when wild type and mutant
PRPF31 are expressed in HEK 293T cells with a C-terminal
EGFP-tag, this solubility difference is lost. Whole cell extracts
and soluble cell extracts of both His-tagged and EGFP-tagged
proteins were subjected to Western analysis using anti-His tag
and anti-EGFP tag antibodies, respectively (Fig. 2). When band
strength was quantified using Genesnap software (Syngene),
this indicated that the ratio of soluble to total expressed PRPF31
protein was substantially lower for the His-tagged mutant
proteins than for wild type (0.72 (WT), 0.39 (A194E mutant)
and 0.24 (A216P mutant)) whereas the ratios for the EGFP-
tagged proteins were comparable (0.87 (WT), 0.80 (A194E
mutant) and 0.90 (A216P mutant)). Indeed, the results showed
that whereas the His-tagged proteins remain largely in the
insoluble fraction, nearly all the expressed EGFP-tagged protein
was recovered in a soluble form.
3.4. Real-time study of nuclear importation of PRPF31
Wild type and mutant EGFP-tagged PRPF31 were expressed
in COS7 cells and examined directly in live cells using a Bio-
Rad Radiance 2000 confocal microscope fitted with a 488-nm
line excitation laser. When the cells were examined at 24 h post-
transfection both wild type and mutant proteins were present in
the nucleus with only a faint fluorescent signal from the
cytoplasm. The cells appeared healthy with well-rounded nuclei.
Fluorescence recovery after photobleaching (FRAP), a dynamic
cell imaging technique, was used to examine the actual rate of
importation of PRPF31-EGFP into the nucleus in these live
transfected cells [14,15]. Nuclei were selectively photobleached by
scanning with the Radiance 488 nm laser; the subsequent recovery
of fluorescence within these nuclei is due to movement ofFig. 2. Comparison of protein solubility of His-tagged and EGFP-tagged
PRPF31 proteins expressed in HEK 293T cells. Whole cell extracts (WCEs) and
soluble cell extracts (SCEs) containing equivalent amounts of total protein were
subjected to western analysis using α-His.tag (upper panel) and α-EGFP (lower
panel) monoclonal antibodies.unbleached PRPF31-EGFP from the cytoplasm. This recovery
was recorded by sequential scanning of the cell (as shown in Fig.
3a). The recovery of cells expressing EGFP alone is also shown for
comparison. Since the amount of PRPF31-EGFP present in the
cytoplasm at the start of the experiment is much lower than for
EGFP itself, the relative recovery is much smaller than the latter
but is nonetheless measurable and reproducible.
The kinetics of fluorescence recovery due to protein
transport across the nuclear membrane was measured after
photobleaching a region of interest (ROI), which in this case
comprised the whole nucleus. Before photobleaching, the mean
fluorescence intensity over the ROI was measured and
photobleaching within the ROI was then achieved using 3
rapid cycles of 100% intensity 488 nm laser light. Sequential
confocal images of the entire cell were then taken, initially at 1-s
intervals for 10 cycles, followed by a further 20 cycles at 10 s
intervals. This FRAP protocol was adopted because the initial
recovery of fluorescence was very fast, necessitating fast data
acquisition, whilst the later stages could be tracked using a
longer cycle time. In this way pigment photobleaching as a
result of sequential scanning was minimised and indeed was
found to be negligible in control experiments.
Fluorescence intensity data from these images were used to
measure nuclear fluorescence recovery as a function of time
(Fig. 3b). FRAP data were normalised to the pre-bleach values,
which were arbitrarily set to 1. The time course of recovery was
fitted to a standard FRAP recovery equation: I=A*(1−exp(−t/
τ))+ Io, where I is the nuclear fluorescence intensity, Io is the
nuclear fluorescence at the start of recovery, A is a scaling
constant and τ is the recovery time constant. This failed to
provide an adequate fit to the early stages of the recovery, when
the rate of fluorescence recovery was fastest (Fig. 3b(i)). We
thus investigated the possibility that the rate of recovery might
include two components, a fast component dominating the early
stages of the recovery and a slower component, which became
significant in the later stages. The standard FRAP equation was
thus fitted to the first 10 data points to provide a theoretical
‘fast’ FRAP curve. This was then deducted from all the
experimental data points which were then fitted with a ‘slow’
FRAP curve. The combined ‘fast+slow’ theoretical curve then
provided a satisfactory fit to the experimental data (Fig. 3b(ii)).
Using this method recovery time constants, τfast and τslow,
were derived from the data for each cell measured and are
presented in Table 1. The recovery time constant for the
slow component of wild type PRPF31-EGFP importation
(78.4±25.4 s) was comparable to the value obtained for the
EGFP control (99.5±1.9 s). In contrast the value for the fast
component of wild type PRPF31-EGFP importation was at
least 12-fold faster (6.31±0.08 s). The values obtained for
the two mutant proteins were not significantly different from
the wild type values for both fast and slow components
(Fig. 3b(iii), (iv) and Table 1).
4. Discussion
In this study, the mechanism of importation of the splicing
factor protein PRPF31 into the nucleus and the impact of two
Fig. 3. FRAP analysis of importation of wild type and mutant PRPF31 proteins into the nuclei of transfected COS7 cells. (a) Confocal images show single z sections of
cells expressing EGFP and wild type PRPF31-EGFP pre-bleach and at the indicated time points post-bleach. (b) Kinetics of fluorescence recovery after nuclear
photobleaching. Datapoints for wild type PRPF31-EGFP failed to fit a standard FRAP recovery curve of form I=A*(1−exp(−t/τ))+ Io (i) but fitted a two component
recovery curve (ii) as described in Results.
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been examined. In order to investigate the interaction of
PRPF31 with proteins from the importin family, the first step
was to purify the wild type protein and the two mutant variants.
A His-tag was used to simplify the purification, but attempts toTable 1




τfast=6.31±0.08 τfast=5.66±0.69 τfast=5.68±0.97 τ=99.5±1.9
τslow=78.4±25.4 τslow=77.1±22.4 τslow=83.3±13.5purify both the wild type and more particularly the mutant
proteins were complicated by protein insolubility and aggrega-
tion. Wild type and mutant proteins were eventually purified
under denaturing conditions and found to re-fold as soluble
proteins on removal of denaturant. Efforts to concentrate the
proteins above 0.1 mg/ml were unsuccessful, however, due to
protein precipitation.
The results of the solubility study indicate that the nature of
the purification tag affects protein solubility. In particular, the
reduced solubility of mutant protein when expressed with a
small His-tag is not seen when expressed with the much larger
24 kDa EGFP protein tag. Moreover, the wild type protein is
more soluble with an EGFP tag, which leads us to suspect that
the addition of this relatively large protein to PRPF31 has the
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differences between the wild type and mutant forms. It is at
present unknown whether untagged mutant PRPF31 gives rise
to solubility problems in the photoreceptors of ADRP patients
but we would propose that the smaller His-tagged version is
more likely to behave like the untagged protein than the version
with the much larger EGFP-tag.
Although we cannot rule out the binding of PRPF31 to
importin α/β heterodimers [10], the finding that PRPF31
interacts directly with importin β1 was unexpected in view of
its possession of what appears to be a classical NLS. Certain
transport substrates have been reported to bind directly to
importin β in the absence of importin α, for example PTHrP
[16], HIV-1 [17] and hnRNP binding proteins [18], but no clear
consensus sequence for this binding has emerged. This finding
should contribute to the definition of the consensus NLSs
required for binding directly to importin β as compared to
importin α/β heterodimers.
Previous studies have indicated that proteins of molecular
size up to 56 kDa are able to move through the nuclear pores
freely by passive diffusion, but that larger proteins require the
assistance of nuclear importation machinery involving both the
importins and Ran-GTP in an energy-dependent process [15].
Using the FRAP technique, movement of EGFP, a protein of 24
kDa, was shown to be by passive diffusion and was independent
of cellular GTP or ATP. However, the movement was slowed
∼100 fold compared to diffusion within the nucleus or
cytoplasm due to the reduced cross-sectional areas of the
nuclear pores themselves [15]. The rate of nuclear importation
of EGFP measured in this study (τ ∼99 s) is rather faster than
previously reported [15], possibly due to experimental differ-
ences between laboratories using this novel technique, but is
broadly consistent with the previous finding. In contrast the size
of the EGFP-tagged PRPF31 protein precludes passive
diffusion. The FRAP analysis of the nuclear importation of
this protein indicated a two component recovery process, a fast
component with kinetics comparable to that for free diffusion
within an unbounded compartment (τ∼6 s), and a slow
component with kinetics comparable to that for passive
diffusion through the nuclear pores (τ∼80 s). Which of these
components represents the importin-assisted passage across the
nuclear membrane? The fast component is similar in magnitude
to the rate of passive diffusion across an unbounded space and
may thus be attributable to movement of unbleached pigment
surviving the photobleaching step from remote areas within the
nucleus. Therefore, the slow component most likely represents
the rate of movement through the nuclear pores. The magnitude
of this rate might suggest that the number and size of the nuclear
pores is the factor controlling the rate of nuclear transport,
whether that process is active or passive.
The experiments presented here are consistent in showing
that the mutant proteins are able to interact with importin and
that the rate of importation of the soluble forms of the wild type
and mutant proteins into the nucleus is the same. This result re-
affirms therefore the importance of the mutant protein
insolubility in the development of disease pathology. Our
previous studies [8] on PRPF31 have shown that, whenexpressed as His-tagged proteins, these two mutations cause
an accumulation of mutant protein in the cytoplasm, presum-
ably as a direct result of protein insolubility, with reduced levels
in the nucleus. The overall consequence of this would be a
reduction in the level of functional protein in the nucleus. In rod
photoreceptor cells, with a very high demand for protein
synthesis, this could result in an insufficiency of splicing
activity. Consistent with this explanation is the finding that
retina-derived primary cultures that express mutant PRPF31
proteins contain reduced concentrations of rhodopsin, normally
the most abundant protein in such cells [9]. The incomplete
penetrance that is common in this form of RP [19] would also fit
this hypothesis: the overall level of PRPF31 production is
determined by variants of the gene that determine transcription
activity, so a high or low production of normal gene product
from the normal allele will result respectively in more or less
splicing capability in photoreceptors and the absence or
presence of pathology.
Schaffert et al. [20] recently showed using PRPF31 knock-
down experiments on live cells that, once inside the nucleus,
PRPF31 cycles between nuclear speckles (the sites of splicing
factor storage), the Cajal bodies (the sites of tri-snRNP
assembly) and the nucleoplasm, and that in the absence of
PRPF31, U4/U6 di-snRNPs and p110 accumulate in the Cajal
bodies, whereas U5 snRNPs largely remain in the speckles. It
will be interesting to discover whether the A194E and A216P
mutations have any effect on this cycling of PRPF31 or on the
pattern of accumulation of other factors within the nucleus.
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